Director Jack R. Lazar sells 7,500 Astera Labs (ALAB) shares

Rhea-AI Filing Summary

Astera Labs, Inc. director Jack R. Lazar reported selling a total of 7,500 shares of common stock in open-market transactions on March 5, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.

The weighted average sale prices ranged from about $117.64 to $123.50 per share across multiple trades. After these transactions, Lazar directly holds 87,351 shares of Astera Labs common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAZAR JACK R

(Last) (First) (Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE CA 95131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		S(1)		1,601	D	$118.1473(2)	93,250	D
Common Stock	03/05/2026		S(1)		3,167	D	$119.4934(3)	90,083	D
Common Stock	03/05/2026		S(1)		1,200	D	$120.222(4)	88,883	D
Common Stock	03/05/2026		S(1)		1,035	D	$121.3046(5)	87,848	D
Common Stock	03/05/2026		S(1)		212	D	$122.0191(6)	87,636	D
Common Stock	03/05/2026		S(1)		285	D	$123.5	87,351	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.6400 to $118.6200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.7700 to $119.6700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $119.8100 to $120.7600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.8800 to $121.8000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $121.9100 to $122.0800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Philip Mazzara, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Astera Labs (ALAB) report in this Form 4?

Astera Labs reported that director Jack R. Lazar sold 7,500 shares of common stock in open-market transactions on March 5, 2026. The filing details share amounts, weighted average prices, and Lazar’s remaining direct ownership after the trades.

How many Astera Labs (ALAB) shares did Jack R. Lazar sell and at what prices?

Jack R. Lazar sold a total of 7,500 shares of Astera Labs common stock. The weighted average prices for the grouped trades ranged from about $117.64 to $123.50 per share, based on multiple transactions within those price ranges.

Was the Astera Labs (ALAB) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales occurred automatically under a Rule 10b5-1 trading plan adopted by Jack R. Lazar on December 2, 2025. Such plans allow pre-scheduled trades according to predetermined instructions set in advance.

How many Astera Labs (ALAB) shares does Jack R. Lazar own after the reported sale?

After the reported transactions, Jack R. Lazar directly owns 87,351 shares of Astera Labs common stock. This post-transaction balance is disclosed in the Form 4 as the total number of shares held following the final sale on March 5, 2026.

What type of transactions did Astera Labs (ALAB) disclose for Jack R. Lazar?

The company disclosed a series of open-market sales of common stock by director Jack R. Lazar. Each trade is coded as an “S” transaction, described as a sale in open market or private transaction, all occurring on March 5, 2026.

How are the sale prices reported in the Astera Labs (ALAB) Form 4 footnotes?

The Form 4 notes that each reported price is a weighted average. Shares were sold in multiple trades within specified ranges, such as $117.6400 to $118.6200. Lazar undertakes to provide exact breakdowns of shares sold at each price upon request.